Winton Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-24,234
| Closed | -$471K | – | 963 |
|
|
2023
Q2 | $471K | Buy |
24,234
+877
| +4% | +$17K | 0.04% | 348 |
|
|
2023
Q1 | $663K | Buy |
23,357
+3,584
| +18% | +$102K | 0.04% | 589 |
|
|
2022
Q4 | $578K | Sell |
19,773
-11,252
| -36% | -$329K | 0.04% | 587 |
|
|
2022
Q3 | $820K | Buy |
31,025
+9,471
| +44% | +$250K | 0.05% | 476 |
|
|
2022
Q2 | $958K | Buy |
21,554
+5,224
| +32% | +$232K | 0.05% | 499 |
|
|
2022
Q1 | $808K | Buy |
16,330
+6,198
| +61% | +$307K | 0.04% | 538 |
|
|
2021
Q4 | $516K | Sell |
10,132
-10,360
| -51% | -$528K | 0.03% | 670 |
|
|
2021
Q3 | $1.14M | Sell |
20,492
-3,968
| -16% | -$221K | 0.06% | 435 |
|
|
2021
Q2 | $1.05M | Sell |
24,460
-2,377
| -9% | -$102K | 0.06% | 507 |
|
|
2021
Q1 | $1.12M | Buy |
26,837
+9,805
| +58% | +$409K | 0.06% | 397 |
|
|
2020
Q4 | $793K | Sell |
17,032
-12,412
| -42% | -$578K | 0.06% | 534 |
|
|
2020
Q3 | $1.25M | Sell |
29,444
-88,299
| -75% | -$3.75M | 0.04% | 717 |
|
|
2020
Q2 | $5.65M | Sell |
117,743
-23,628
| -17% | -$1.13M | 0.15% | 170 |
|
|
2020
Q1 | $6.5M | Sell |
141,371
-12,853
| -8% | -$591K | 0.17% | 160 |
|
|
2019
Q4 | $9.27M | Buy |
154,224
+147,848
| +2,319% | +$8.88M | 0.13% | 259 |
|
|
2019
Q3 | $361K | Buy |
6,376
+730
| +13% | +$41.3K | ﹤0.01% | 1204 |
|
|
2019
Q2 | $314K | Buy |
+5,646
| New | +$314K | 0.01% | 874 |
|
|
2019
Q1 | – | Sell |
-237,080
| Closed | -$9.55M | – | 1208 |
|
|
2018
Q4 | $9.55M | Buy |
+237,080
| New | +$9.55M | 0.21% | 213 |
|